[en] Class D β-lactamases exhibit very heterogeneous hydrolysis activity spectra against the various types of clinically useful β-lactams. Similarly, and according to the available data, their sensitivities to inactivation by avibactam can vary by a factor of more than 100. In this paper, we performed a detailed kinetic study of the interactions between two ceftazidime-hydrolyzing OXA enzymes and showed that they were significantly more susceptible to avibactam than several other class D enzymes that do not hydrolyze ceftazidime. From a clinical point of view, this result is rather interesting if one considers that avibactam is often administered in combination with ceftazidime.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Frère, Jean-Marie ; Université de Liège - ULiège > Département des sciences de la vie > Macromolécules biologiques
Bogaerts, P.; National Reference Laboratory for Monitoring of Antimicrobial Resistance in Gram-Negative Bacteria, CHU Dinant-Godinne, UCL Namur, B 5530 Yvoir, Belgium
Huang, T.-D.; National Reference Laboratory for Monitoring of Antimicrobial Resistance in Gram-Negative Bacteria, CHU Dinant-Godinne, UCL Namur, B 5530 Yvoir, Belgium
Bush, K. Past and present perspectives on β-lactamases. Antimicrob. Agents Chemother. 2018, 62. [CrossRef] [PubMed]
Bush, K.; Bradford, P.A. Interplay between β-lactamases and β-lactamase inhibitors. Nat. Rev. Microbiol. 2019, 17, 295–306. [CrossRef] [PubMed]
Frère, J.M. (Ed.) B-Lactamases; Nova Science Publishers: New York, NY, USA, 2012.
Bunyak, J. β-Lactams as Unhibitors of β-Lactamases in B-Lactamases; Frère, J.M., Ed.; Nova Science Publishers: New York, NY, USA, 2012; pp. 217–258.
Prosperi-Meys, C.; Llabres, G.; de Seny, D.; Soto, R.P.; Valladares, M.H.; Frère, J.M.; Galleni, M. Interaction between class B β-lactamases and suicide substrates of active-site serine β-lactamases. FEBS Lett. 1999, 443, 109–111. [CrossRef]
Dortet, L.; Oueslati, S.; Jeannot, K.; Tandé, D.; Naas, T.; Nordmann, P. Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum β-lactamase without significant carbapenemase activity. Antimicrob. Agents Chemother. 2015, 59, 3823–3828. [CrossRef]
Oueslati, S.; Nordmann, P.; Poirel, L. Heterogeneous hydrolytic features for OXA-48-like β-lactamases. J. Antimicrob. Chemother. 2015, 70, 1059–1063. [CrossRef]
Poirel, L.; Castanheira, M.; Carrër, A.; Rodriguez, C.P.; Jones, R.N.; Smayevsky, J.; Nordmann, P.L. OXA-163, an OXA-48-related class D β-lactamase with extended activity toward expanded-spectrum cephalosporins. Antimicrob. Agents Chemother. 2011, 55, 2546–2551. [CrossRef]
Dortet, L.; Naas, T. Noncarbapenemase OXA-48 Variants (OXA-163 and OXA-405) Falsely Detected as Carbapenemases by the β Carba Test. J. Clin. Microbiol. 2017, 55, 654–655. [CrossRef]
Arlet, G.; Decré, D.; Lavollay, M.; Podglajen, I. Reply to “Noncarbapenemase OXA-48 Variants (OXA-163 and OXA-405) Falsely Detected as Carbapenemases by the β Carba Test”. J. Clin. Microbiol. 2017, 55, 656–657. [CrossRef]
Pasteran, F.; Denorme, L.; Ote, I.; Gomez, S.; De Belder, D.; Glupczynski, Y.; Bogaerts, P.; Ghiglione, B.; Power, P.; Mertens, P.; et al. Rapid Identification of OXA-48 and OXA-163 Subfamilies in Carbapenem-Resistant Gram-Negative Bacilli with a Novel Immunochromatographic Lateral Flow Assay. J. Clin. Microbiol. 2016, 54, 2832–2836. [CrossRef]
Abdelaziz, M.O.; Bonura, C.; Aleo, A.; El-Domany, R.A.; Fasciana, T.; Mammina, C. OXA-163-producing Klebsiella pneumoniae in Cairo, Egypt, in 2009 and 2010. J. Clin. Microbiol. 2012, 50, 2489–2491. [CrossRef]
Bogaerts, P.; Naas, T.; Saegeman, V.; Bonnin, R.A.; Schuermans, A.; Evrard, S.; Bouchahrouf, W.; Jove, T.; Tande, D.; de Bolle, X.; et al. OXA-427, a new plasmid-borne carbapenem-hydrolysing class D β-lactamase in Enterobacteriaceae. J. Antimicrob. Chemother. 2017, 72, 2469–2477. [CrossRef] [PubMed]
Desmet, S.; Nepal, S.; van Dijl, J.M.; Van Ranst, M.; Chlebowicz, M.A.; Rossen, J.W.; Van Houdt, J.K.J.; Maes, P.; Lagrou, K.; Bathoorn, E. Antibiotic Resistance Plasmids Cointegrated into a Megaplasmid Harboring the blaOXA-427 Carbapenemase Gene. Antimicrob. Agents Chemother. 2018, 62, e01448. [CrossRef] [PubMed]
De Laveleye, M.; Huang, T.D.; Bogaerts, P.; Berhin, C.; Bauraing, C.; Sacré, P.; Noel, A.; Glupczynski, Y. multicenter study group. Increasing incidence of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in Belgian hospitals. Eur. J. Clin. Microbiol. Infect. Dis. 2017, 36, 139–146. [CrossRef] [PubMed]
Ehmann, D.E.; Jahic, H.; Ross, P.L.; Gu, R.F.; Hu, J.; Durand-Réville, T.F.; Lahiri, S.; Thresher, J.; Livchak, S.; Gao, N.; et al. Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. J. Biol. Chem. 2013, 288, 27960–27971. [CrossRef]
Lahiri, S.D.; Mangani, S.; Jahić, H.; Benvenuti, M.; Durand-Reville, T.F.; De Luca, F.; Ehmann, D.E.; Rossolini, G.M.; Alm, R.A.; Docquier, J.D. Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: A structure-guided study of OXA-24 and OXA-48. ACS Chem. Biol. 2015, 10, 591–600. [CrossRef]
Bou, G.; Oliver, A.; Martínez-Beltrán, J. OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob. Agents Chemother. 2000, 44, 1556–1561. [CrossRef]
De Meester, F.B.; Joris, B.; Reckinger, G.; Bellefroid-Bourguignon, C.; Frère, J.M.; Waley, S.G. Automated analysis of enzyme inactivation phenomena. Application to-lactamases and D-peptidases. Biochem. Pharmacol. 1987, 36, 2393–2403. [CrossRef]
Nukaga, M.; Papp-Wallace, K.M.; Hoshino, T.; Lefurgy, S.T.; Bethel, C.R.; Barnes, M.D.; Zeiser, E.T.; Johnson, J.K.; Bonomo, R.A. Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam. Antimicrob. Agents Chemother. 2018, 62, e02371. [CrossRef]
Ruggiero, M.; Papp-Wallace, K.M.; Taracila, M.A.; Mojica, M.F.; Bethel, C.R.; Rudin, S.D.; Zeiser, E.T.; Gutkind, G.; Bonomo, R.A.; Power, P. Exploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 β-Lactamase. Antimicrob. Agents Chemother. 2017, 61. [CrossRef]
Ehmann, D.E.; Jahić, H.; Ross, P.L.; Gu, R.F.; Hu, J.; Kern, G.; Walkup, G.K.; Fisher, S.L. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc. Natl. Acad. Sci. USA 2012, 109, 11663–11668. [CrossRef]
Yoshizumi, A.; Ishii, Y.; Aoki, K.; Testa, R.; Nichols, W.W.; Tateda, K. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations. J. Infect. Chemother. 2015, 21, 148–151. [CrossRef] [PubMed]
Vázquez-Ucha, J.C.; Maneiro, M.; Martínez-Guitián, M.; Buynak, J.; Bethel, C.R.; Bonomo, R.A.; Bou, G.; Poza, M.; González-Bello, C.; Beceiro, A. Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii. Antimicrob. Agents Chemother. 2017, 61, e01172. [CrossRef] [PubMed]
Hall, L.M.; Livermore, D.M.; Gur, D.; Akova, M.; Akalin, H.E. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1993, 37, 1637–1644. [CrossRef] [PubMed]
Kaitany, K.C.; Klinger, N.V.; June, C.M.; Ramey, M.E.; Bonomo, R.A.; Powers, R.A.; Leonard, D.A. Structures of the class D Carbapenemases OXA-23 and OXA-146: Mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins, and aztreonam. Antimicrob. Agents Chemother. 2013, 57, 4848–4855. [CrossRef] [PubMed]
